Chronic myeloid leukaemia
Not recruitingStudy of dose reduction strategy for tyrosine kinase inhibitors (imatinib, ponatinib, bosutinib, nilotinib, dasatinib) in patients with chronic myeloid leukemia
Study of dose reduction strategy for tyrosine kinase inhibitors (imatinib, ponatinib, bosutinib, nilotinib, dasatinib) in patients with chronic myeloid leukemia
- Disease:Chronic myeloid leukaemia
- Substances:BosutinibDasatinib+3
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Bosutinib
- Sponsor:Stichting Radboud universitair medisch centrum









